CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-12 | Boyer David W. Chief Corp. Affairs Officer | Grant or award · Restricted Stock Unit 10b5-1 | +6,401 | 6,401 | ||
| 2025-02-12 | BENEVICH ERIC Chief Commercial Officer | Grant or award · Stock Option 10b5-1 | +42,805 | 42,805 | ||
| 2025-02-12 | BENEVICH ERIC Chief Commercial Officer | Grant or award · Restricted Stock Unit 10b5-1 | +8,022 | 8,022 | ||
| 2025-02-12 | ABERNETHY MATT Chief Financial Officer | Grant or award · Stock Option 10b5-1 | +45,538 | 45,538 | ||
| 2025-02-12 | ABERNETHY MATT Chief Financial Officer | Grant or award · Restricted Stock Unit 10b5-1 | +8,534 | 8,534 | ||
| 2025-02-10 | Cooke Julie Chief Human Resources Officer | Sale 10b5-1 | −700 | $118.28 | $83K | 18,831 |
| 2025-02-10 | GORMAN KEVIN CHARLES Director | Sale 10b5-1 | −2,274 | $118.37 | $269K | 519,074 |
| 2025-02-10 | ROBERTS EIRY Chief Medical Officer | Sale 10b5-1 | −980 | $118.22 | $116K | 33,253 |
| 2025-02-10 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 | −911 | $118.25 | $108K | 41,679 |
| 2025-02-10 | Gano Kyle Chief Executive Officer | Sale 10b5-1 | −980 | $118.39 | $116K | 137,658 |
| 2025-02-10 | Boyer David W. Chief Corp. Affairs Officer | Sale 10b5-1 | −700 | $118.31 | $83K | 1,998 |
| 2025-02-10 | BENEVICH ERIC Chief Commercial Officer | Sale 10b5-1 | −980 | $118.31 | $116K | 42,799 |
| 2025-02-10 | ABERNETHY MATT Chief Financial Officer | Sale 10b5-1 | −980 | $118.27 | $116K | 33,561 |
| 2025-02-08 | Cooke Julie Chief Human Resources Officer | Option exercise 10b5-1 | +1,329 | 19,531 | ||
| 2025-02-08 | Cooke Julie Chief Human Resources Officer | Option exercise · Restricted Stock Unit 10b5-1 | −1,329 | 0 | ||
| 2025-02-08 | GORMAN KEVIN CHARLES Director | Option exercise 10b5-1 | +4,318 | 521,348 | ||
| 2025-02-08 | GORMAN KEVIN CHARLES Director | Option exercise · Restricted Stock Unit 10b5-1 | −4,318 | 0 | ||
| 2025-02-08 | ROBERTS EIRY Chief Medical Officer | Option exercise 10b5-1 | +1,860 | 34,233 | ||
| 2025-02-08 | ROBERTS EIRY Chief Medical Officer | Option exercise · Restricted Stock Unit 10b5-1 | −1,860 | 0 | ||
| 2025-02-08 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 | +1,727 | 42,590 |
Page 24 of 49 · 963 trades